Novartis Gene Therapies Chooses Right to Work Texas for Next Location
Novartis Gene Therapies is investing an impressive $280 million in order to establish a new location in Right to Work Denton, Texas. This goes to show that Right to Work states attract great businesses. In addition, the company will also create 150 new jobs.
From Area Development Magazine:
“RLT has the potential to revolutionize cancer care. […] The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.” […]
“Texas is a leading biotech hub and home to groundbreaking advancements in medicine. […] This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”
To read the previous economic update on Right to Work states, click here.